Heparin Market Report 2025

This Heparin market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The heparin market size has grown strongly in recent years. It will grow from $9.75 billion in 2024 to $10.33 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increased prevalence of cardiovascular diseases, advances in surgical procedures requiring anticoagulation, growth inThe aging population, rise in deep vein thrombosis cases, expansion of applications in renal dialysis.

The heparin market size is expected to see strong growth in the next few years. It will grow to $13.91 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for low-molecular-weight heparin, expansion of heparin use in the treatment of cancer, increasing incidence of venous thromboembolism, development of biosynthetic heparin, increase in the number of emerging markets. Major trends in the forecast period include technological advancements in heparin production, emphasis on the production of safer and more bioavailable heparin, integration of digital technologies in heparin administration, adoption of biosimilars, exploration of heparin alternatives and substitutes.

The rising prevalence of chronic diseases is a significant factor driving the growth of the heparin market. Chronic diseases are defined as medical conditions lasting more than a year that necessitate ongoing medical attention or hospitalization for specialized treatment. Factors such as changing lifestyles, poor eating habits, and inadequate weight management contribute to the rise of these conditions, with some prolonged chronic infections increasing the risk of cancer. The heightened incidence of such diseases has led to a growing demand for heparin, which is commonly used to thin the blood during surgeries and various medical treatments. For example, in April 2023, the World Health Organization (WHO) reported that approximately 537 million adults aged 20-79 worldwide are living with diabetes, with projections suggesting this figure could rise to 643 million by 2030 and 783 million by 2045. Thus, the increasing prevalence of chronic diseases is expected to drive growth in the heparin market.

The increasing number of surgical procedures is anticipated to significantly enhance the growth of the heparin market. A surgical procedure is a medical intervention that involves making incisions or employing minimally invasive techniques to access and manipulate the body's tissues or organs. The rising volume of surgical interventions necessitates the use of heparin, an anticoagulant, to prevent blood clots during and after surgery, thereby driving demand for heparin. For instance, in February 2024, the American Academy of Facial Plastic and Reconstructive Surgery, a US-based non-profit organization, reported that approximately 83% of all medical procedures performed in 2023 were minimally invasive, while traditional surgical procedures accounted for the remaining 17%. Additionally, the American Society of Plastic Surgeons, a US-based specialty organization, indicated that the total number of cosmetic minimally invasive procedures rose from 23.7 million in 2022 to 25.4 million in 2023. Therefore, the rise in surgical procedures is expected to propel the growth of the heparin market.

Leading companies in the heparin market are concentrating on developing innovative solutions to enhance drug efficacy, improve safety profiles, and minimize side effects, while also exploring advanced delivery methods and biosimilar development to address the increasing global demand. Heparin Sodium Chloride Injection is a sterile solution that combines heparin, an anticoagulant (blood thinner), with sodium chloride, which is commonly used to maintain osmotic balance and stability in the solution. For example, in February 2024, B. Braun Medical Inc., a US-based medical company, introduced Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection, available in a 1,000 mL EXCEL IV container at a concentration of 2 units/mL. This product represents the fifth addition to B. Braun's Heparin portfolio and is specifically designed to meet the diverse needs of healthcare facilities for this essential anticoagulant medication.

Major companies operating in the heparin market are adopting strategic partnerships approach to provide the manufacturing efficiency of bioengineered heparin to individuals, businesses, and governments. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in January 2022, Optimvia, a US-based biopharmaceutical company, partnered with Ginkgo Bioworks, a US-based biotech company. Optimvia officials aim to utilize Ginkgo's cell and enzyme engineering platform to enhance their biosynthetic heparin manufacturing technology. Additionally, they seek to leverage Ginkgo's expertise in fermentation process development to expedite the performance improvements of their heparin production.

In May 2022, Fresenius Kabi, a Germany-based healthcare company, acquired Ivenix Inc. for an undisclosed amount. The integration of Ivenix's top-notch hardware and software solutions with Fresenius Kabi's intravenous fluids and infusion devices will establish an extensive and leading portfolio of high-quality products. This lays a robust and fast-paced foundation to foster sustainable expansion within the high-value MedTech sector. Ivenix Inc. is a US-based medical technology company.

Major companies operating in the heparin market include Baxter International Inc., B. Braun Medical Inc., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leo Pharma A/S, Aspen Pharmacare plc, Bioiberica SA, Biomedical Foscama Group, Biovet SA, Changzhou Qianhong Bio-pharma Co. Ltd., CSPC NBP Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., Nanjing King-friend Biochemical Pharmaceutical Co. Ltd., Opocrin Pharmaceuticals Ltd., Pfizer Inc., Pharma Action Ltd., Rovi Pharma Industrial Services Ltd., Sagent Pharmaceuticals Inc., Sanofi S. A., Shenzhen Hepalink Pharmaceutical Co. Ltd., Sichuan Deebio Pharmaceutical Co. Ltd., Teva Pharmaceuticals Industries Ltd., VAV Life Sciences Inc., Viatris Inc., Wanbang Biopharmaceuticals Co. Ltd., Wockhardt Ltd., Xinbai Pharmaceuticals Co. Ltd., Yino Pharma Co. Ltd.

North America was the largest region in the heparin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heparin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the heparin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Heparin refers to an anticoagulant type substance that slows the development of blood clots. Heparin is produced by the liver, lungs, and other human tissues, but it can also be produced in a lab. In order to prevent or dissolve blood clots, heparin may be injected into muscle or blood. Heparin is widely used in hospitals to prevent excessive coagulation during cardiac surgery, extracorporeal circulation, or dialysis.

The main types of heparin include unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). The unfractionated heparin (UFH) market refers to a class of fast-acting anticoagulant medication that prevents clot formation by combining with antithrombin. Unfractionated heparin binds to antithrombin and improves its ability to inhibit two of the body's most powerful clotting factors, factor Xa and factor IIa, in minutes. They are sourced from bovine or porcine and administered intravenous or subconscious. they are used in the treatment of venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease, and others. They are distributed through hospital pharmacies, drug stores or retail pharmacies, and online pharmacies.

The heparin market research report is one of a series of new reports that provides heparin market statistics, including heparin industry global market size, regional shares, competitors with a heparin market share, detailed heparin market segments, market trends and opportunities, and any further data you may need to thrive in the heparin industry. This heparin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The heparin market consists of sales of enoxaparin, dalteparin, and nadroparin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.